Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Compugen

Roche Holding AG

Here are the hottest companies coming up in the biotech sector next month.

2 Top Biotech Picks for May

Brookfield Renewable Partners

Mastercard

Uncle Sam could be sending more money your way in the not-too-distant future. Buying these stocks will put the extra cash to good use.

3 Great Stocks to Buy If You Get a Second Stimulus Check

Chegg

Nautilus

Sprouts Farmers Markets

VeriSign

A few positive developments on the vaccine front, unprecedented economic help, reopening of economies and some bullish economic datapoints should facilitate growth stocks ahead.

5 Reasons Why Growth Stocks Will Soar Further

Dropbox

MarketAxess Holdings

QuidelOrtho Corp

Half of this month is already over, yet Wall Street is in green defying the well-known financial-world adage "Sell in May and go away."

Major Indexes Defying "Sell in May" Adage: 5 Growth Picks

Bull of the Day: Vertex Pharma (VRTX)

Vertex Pharmaceuticals (VRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Surging Earnings Estimates Signal Good News for Vertex Pharmaceuticals (VRTX)

Advanced Semiconductor Engineering

Hain Celestial Group

Murphy USA

Wall Street poised to gain after Powell expressed confidence that the U.S. economy will recover beginning summer.

Wall Street to Rally as Powell Talks Recovery: 5 Big Winners

Vertex Pharmaceuticals (NASDAQ: VRTX) shares are trading higher after Argus Research maintained a Buy rating on the stock and raised its price target from $270 to $320.

Why Vertex's Stock Is Trading Higher Today

Vertex Energy

Vertex Energy, Inc. (VTNR) CEO Ben Cowart on Q1 2020 Results - Earnings Call Transcript

M17, the Taiwan-based live streaming entertainment startup, announced that it has raised a $26.5 million Series D. The round was led by Vertex Growth Fund, with participation from Stonebridge Korea Unicorn Venture Fund, Innoven Capital Singapore, Kaga Electronics and ASE Global Group.

Taiwan-based live streaming company M17 raises $26.5 million Series D led by Vertex Growth

BioMarin Pharmaceutical

Incyte

Eli Lilly

Regeneron Pharmaceuticals

We are only in May, but 2020 is already one of the most incredible years in stock market history.

5 Top Health Care Stocks to Buy Now on the Goldman Sachs Conviction List

BJ`s Wholesale Club Holdings Inc

Stocks finished last week in the green despite massive job losses as the market expects a sharp but short recession.

Wall Street Resilient to Crisis-Era Jobless Rate: 5 Picks

Gilead Sciences

Novavax

These hot biotech stocks should be near the top of your list.

3 Top Biotech Stocks to Buy in May

Amgen

Bristol-Myers

Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing.

5 Biopharmas Where BofA Would Put Its Money To Work

AppFolio

Domino's Pizza

Netflix

We have selected four solid stocks that have striking earnings growth and positive estimate revisions.

4 Best Stocks to Buy for Stellar Earnings Growth

Vertex Pharmaceuticals’ stock has been providing market-beating returns of late. Here’s why it can continue outperforming.

3 Reasons to Buy Vertex Pharmaceuticals Stock Right Now

Tradeweb Markets

3 Market-Beating Growth Stocks

Clorox

Logitech

MACOM Technology Solutions Holdings

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

5 Stocks That Look Appealing on Relative Price Strength

Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Vertex (VRTX) Run Higher on Rising Earnings Estimates?

Aphria

Activision Blizzard

Guardant Health Inc

Shopify

Forget earnings growth, bet on these top-ranked stocks to cash in on earnings beat.

5 Top-Ranked Stocks to Tap Earnings Beat Potential

Advanced Micro Devices

Cboe Global Markets

CME Group

Intercontinental Exchange

Nasdaq

ServiceNow

Prologis

We’re right in the thick of first-quarter earnings season, and while it is looking bad as consumers and companies suffer from the coronavirus shutdown, there are still companies that are growing rapidly.

Deep Dive: These 10 S&P 500 companies increased sales faster than Amazon in a coronavirus-tainted quarter

B2Gold

Cogent Communications Holdings

Driehaus strategy is perfect for investors who have the propensity to take high levels of risk.

4 Momentum Picks Screened - on Driehaus Strategy

There are three great reasons to buy this stock sooner rather than later.

Here's My  Top Stock to Buy in May

Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

Vertex (VRTX) Q1 Earnings Beat, Trikafta Drives CF Revenues

Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani on Q1 2020 Results - Earnings Call Transcript

News for Vertex Pharmaceuticals Stock (VRTX)